Skip to main content Back to Top
Advertisement

10/2/2019

Diclofenac Potassium Tablets

Products Affected - Description

    • Diclofenac potassium oral tablet, Teva, 50 mg, bottle, 100 count, NDC 00093-0948-01
    • Diclofenac potassium oral tablet, Teva, 50 mg, bottle, 500 count, NDC 00093-0948-05

Reason for the Shortage

    • Mylan has diclofenac potassium tablets available.
    • Teva did not provide a reason for the shortage.
    • Sandoz discontinued diclofenac potassium tablets.

Available Products

    • Diclofenac potassium oral tablet, Mylan, 50 mg, bottle, 100 count, NDC 00378-2474-01

Estimated Resupply Dates

    • Teva has diclofenac potassium 50 mg tablets in 100 count and 500 count on back order and the company estimates a release date of late-October 2019.

Updated

Updated October 2, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 28, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins